Orion Corporation

Earlier this week, we had the pleasure of hosting the Finnish financial media (Taloustoimittajat ry) at Orion’s New York office 🗽 The main topic was Orion’s research and development, particularly pain research, which is a significant area of interest in the U.S. market. Thank you to our guests and the presenters (from left to right): Catherine Akello-Opio, Outi Vaarala, Heikki Mansikka, Arvind Narayana!

Over the past few decades, we’ve witnessed significant advances in breast cancer treatment, making a diagnosis no longer a death sentence. 🙏 However, there is still much work to be done. That’s why researchers are developing next-generation cancer therapies that are more precise, personalized, and often better tolerated. 🔬 #BreastCancer #CancerTreatment #Orion

We are committed to science and sustainability 🌍 We believe that industry plays a key part in tackling climate change, and we want to be part of the solution. Orion's near-term emissions reduction targets have now been validated by the Science Based Targets initiative. Read our article to discover how we’re working to meet our ambitious climate targets. Check the link in the comments 👇 #ResponsiblyForward #Sustainability #SBTi #ScienceBasedTargets #Orion

Orionin koulutukset kiinnostavat!   Orion järjesti torstaina 3.10. farmaseuttiselle henkilökunnalle koulutuksen aiheesta "Biologisten reumalääkkeiden apteekkivaihto biosimilaareihin". Osallistujina oli lähes 800 tiedonjanoista farmasistia. Poikkitieteellisessä koulutuksessa puhujina toimivat reumahoitaja, apteekin proviisori sekä reumatologi. Tilaisuuden mielenkiintoisuudesta ja tarpeellisuudesta kertoi kymmenien kysymysten tulva jokaisen puhujan esityksen jälkeen. Onnistumisesta antoi viitteitä myös NPS (nettosuositteluindeksi), joka oli tähän mennessä saadun palautteen perusteella huippukorkea, peräti 71.   Kiitos Orion kouluttaa -tilaisuuden osallistujille sekä Orionilaisille järjestäjille!   #orionkouluttaa #orionpharma

Every year, around 2.3 million women globally are diagnosed with breast cancer. It is the most common form of cancer in women. One of them is Kerly Hiltunen, who was diagnosed with metastatic breast cancer seven years ago at the age of 41. Kerly says that her diagnosis has made her a different person – in some respects, in a positive way. Read Kerly Hiltunen’s touching story 👇 #BreastCancer #Orion

We are pleased to announce our collaboration with Aitia to create new Gemini Digital Twins to help in the fight against cancer. 🤝 Cancer is a critical global health issue, affecting millions of people worldwide and imposing a significant burden on healthcare systems. The collaboration between Orion and Aitia to discover and develop new medicines for cancer aims to address this need. “We are excited to collaborate with Aitia to harness the power of their Gemini Digital Twins and Causal AI technology in the discovery and development of new cancer treatments. Working with them gives us an opportunity to push the boundaries of what's possible,” says Outi Vaarala, Senior Vice President, Innovative Medicines and Research & Development at Orion.   #CancerResearch #AI #MedicineDiscovery #PharmaInnovation 

Exciting news! Science Based Targets initiative (SBTi) has validated Orion’s near-term climate targets, affirming our commitment to reducing greenhouse gas emissions in line with the latest climate science. 🌍✨ This validation underscores our dedication to science and sustainability. Read about our journey towards a more sustainable future and the concrete measures we are taking from our press release: https://lnkd.in/dJqt97qz #Sustainability #Climate #Orion

Outi Vaarala, Orion’s Senior Vice President, Innovative Medicines and Research & Development discussed our world-class research and development in Kauppalehti, Finland’s leading financial media. Inventing a medicine that can help patients worldwide is rare, and it’s remarkable that researchers in Finland have succeeded in it. Orion plans to increasingly commercialize its new innovative medicines independently in the future, which requires conducting clinical medical research also in the United States. Read the whole article (for subscribers, in Finnish) ⬇️ #PharmaceuticalResearch #PharmaInnovation

Comprehensive induction, a warm and relaxed work community, and plenty of valuable work experience — this and much more is what we offered our Phase1 trainees this past summer. Read what our summer trainees have shared about their experience 👇 #Phase1 #TraineeProgramme #SummerTrainee #Orion

Our innovative molecule, invented by Orion’s scientists in a project that started almost 20 years ago, has become the biggest Orion-originated medicine innovation from Finland ever. With this medicine manufactured completely in our own production sites in Finland, we are serving patients with prostate cancer worldwide.   The medicine’s annual in-market sales booked by our partner Bayer have now exceeded one billion euros for the current year.  “This is a historic achievement for Orion and yet another proof of the high-quality research and development work we have been doing for years,” says Liisa Hurme, Orion’s President & CEO. We are dedicated to continuing to support patients all over the world. This is what building well-being means for us.   #PharmaceuticalResearch #PharmaInnovation #ProstateCancer